Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy
NCT03333551Phase 4Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Florbetapir in cardiac amyloidosis, sponsored by Medical College of Wisconsin. Primary endpoint: Relative Change in Cardiac Uptake of 18F Florbetapir Prior to Chemotherapy and After Six Months of Chemotherapy at 6 months. Started Oct 2020; status: terminated.
02
Drugs
Florbetapir
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03333551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333551.